MCKENNA NEVILLE: Open Payments
NPI 1639721293 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,425 in 76 payments from 15 companies in 2025. Trend: 2023 $770 · 2024 $1,502 · 2025 $1,425
Food & beverage: $1,425
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $296 |
| ABBVIE INC. | 13 | $259 |
| Novo Nordisk Inc | 17 | $257 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $98 |
| Amgen Inc. | 6 | $91 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $91 |
| PFIZER INC. | 4 | $68 |
| GlaxoSmithKline, LLC. | 3 | $53 |
| Lilly USA, LLC | 2 | $44 |
| Merck Sharp & Dohme LLC | 2 | $41 |
Products named: AIRSUPRA, VRAYLAR, QULIPTA, CAPLYTA, BYETTA, XIFAXAN, BREZTRI, Rybelsus.
Industry payments across AZ — which companies pay providers there.
